BetterLife Pharma Inc (NPAU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BetterLife Pharma Inc (NPAU) has a cash flow conversion efficiency ratio of 0.030x as of July 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-172.31K ≈ $-201.45K USD) by net assets (€-5.81 Million ≈ $-6.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BetterLife Pharma Inc (NPAU) defensive interval to measure how many days the company can operate on defensive assets alone.
BetterLife Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how BetterLife Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BetterLife Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BetterLife Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strike Resources Ltd
AU:SRK
|
-0.102x |
|
Trainers House Oyj
HE:TRH1V
|
0.039x |
|
Maschinenfabrik HEID AG
VI:HED
|
N/A |
|
SG COMPANY S.P.A.
F:7KZ
|
N/A |
|
Noronex Ltd
AU:NRX
|
-2.126x |
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
-0.195x |
|
Adalta Ltd
AU:1AD
|
2.240x |
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
-0.079x |
Annual Cash Flow Conversion Efficiency for BetterLife Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of BetterLife Pharma Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see BetterLife Pharma Inc (NPAU) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | €-7.36 Million ≈ $-8.61 Million |
€-2.02 Million ≈ $-2.36 Million |
0.275x | -14.52% |
| 2024-01-31 | €-7.70 Million ≈ $-9.00 Million |
€-2.47 Million ≈ $-2.89 Million |
0.321x | +60.97% |
| 2023-01-31 | €-7.53 Million ≈ $-8.81 Million |
€-1.50 Million ≈ $-1.76 Million |
0.200x | -93.09% |
| 2022-01-31 | €-3.88 Million ≈ $-4.54 Million |
€-11.20 Million ≈ $-13.10 Million |
2.887x | +85.82% |
| 2021-01-31 | €-4.61 Million ≈ $-5.39 Million |
€-7.16 Million ≈ $-8.38 Million |
1.553x | +152.37% |
| 2020-01-31 | €2.66 Million ≈ $3.11 Million |
€-7.88 Million ≈ $-9.21 Million |
-2.966x | -121.11% |
| 2019-01-31 | €3.51 Million ≈ $4.10 Million |
€-4.71 Million ≈ $-5.50 Million |
-1.342x | -113.38% |
| 2018-01-31 | €-55.99K ≈ $-65.46K |
€-561.52K ≈ $-656.48K |
10.029x | +5290.49% |
| 2017-01-31 | €-1.93 Million ≈ $-2.26 Million |
€-359.45K ≈ $-420.23K |
0.186x | -- |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more